Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Trastuzumab Deruxtecan”

127 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 127 results

Large-scale testing (Phase 3)Looking for participantsNCT06643585
What this trial is testing

Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse

Who this might be right for
Breast Cancer
Prof. Wolfgang Janni 180
Not applicableLooking for participantsNCT06846996
What this trial is testing

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China

Who this might be right for
HER2-positive Gastric CancerHER2-positive Gastroesophageal Junction
Daiichi Sankyo 260
Early research (Phase 1)Looking for participantsNCT07015697
What this trial is testing

Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Who this might be right for
Recurrent or Metastatic Solid Tumors
Daiichi Sankyo 76
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07151586
What this trial is testing

Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsNeoplasm MetastasisHER 2 Low-expressing Breast Cancer
UNICANCER 260
Testing effectiveness (Phase 2)Active Not RecruitingNCT04644068
What this trial is testing

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Who this might be right for
Ovarian CancerBreast CancerPancreatic Cancer+10 more
AstraZeneca 702
Testing effectiveness (Phase 2)Active Not RecruitingNCT04538742
What this trial is testing

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AstraZeneca 245
Testing effectiveness (Phase 2)Looking for participantsNCT06525298
What this trial is testing

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Who this might be right for
Advanced Solid TumorHomologous Recombination DeficiencyHRR Deficiency
Eisbach Bio GmbH 144
Post-approval studies (Phase 4)Looking for participantsNCT07195344
What this trial is testing

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

Who this might be right for
Locally Advanced or Metastatic Breast Cancers
Institut Claudius Regaud 210
Large-scale testing (Phase 3)Looking for participantsNCT05950945
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Daiichi Sankyo 250
Large-scale testing (Phase 3)Active Not RecruitingNCT03734029
What this trial is testing

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Who this might be right for
Breast Cancer
Daiichi Sankyo 557
Early research (Phase 1)Looking for participantsNCT04686305
What this trial is testing

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca 244
Testing effectiveness (Phase 2)Active Not RecruitingNCT04639219
What this trial is testing

T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

Who this might be right for
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
AstraZeneca 102
Not applicableStudy completedNCT05458401
What this trial is testing

EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan

Who this might be right for
HER2-positive Breast Cancer
Daiichi Sankyo 256
Testing effectiveness (Phase 2)Looking for participantsNCT04379596
What this trial is testing

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

Who this might be right for
Gastric Cancer
AstraZeneca 413
Post-approval studies (Phase 4)Not Yet RecruitingNCT06245824
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial

Who this might be right for
Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 51
Large-scale testing (Phase 3)Looking for participantsNCT06467357
What this trial is testing

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Who this might be right for
Biliary Tract Cancer
AstraZeneca 620
Testing effectiveness (Phase 2)Looking for participantsNCT06533826
What this trial is testing

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

Who this might be right for
Breast CancerHER2-low Breast CancerMetastatic Breast Cancer+1 more
Ana C Garrido-Castro, MD 357
Not applicableLooking for participantsNCT06928818
What this trial is testing

Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea

Who this might be right for
Cancer of BreastTrastuzumab EmtansineTrastuzumab Deruxtecan
Seoul National University Hospital 100
Testing effectiveness (Phase 2)Looking for participantsNCT05900206
What this trial is testing

Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Karolinska University Hospital 370
Large-scale testing (Phase 3)Active Not RecruitingNCT04494425
What this trial is testing

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
AstraZeneca 866
Load More Results